echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The FDA approved Karyopharm's Xpovio (selinexor) for the treatment of multiple myeloma

    The FDA approved Karyopharm's Xpovio (selinexor) for the treatment of multiple myeloma

    • Last Update: 2020-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Multiple myeloma is a malignant tumor that invades the bone marrow due to abnormal growth of plasma cells.
    multiple myeloma is mostly asymptomatic at first, if the disease worsens, there will be bone pain, often infected, anemia symptoms.
    Karyopharm Therapeutics said recently that the FDA has approved Xpovio (selinexor) in combination with boronazome and dexamisson for the treatment of adult patients with multiple myeloma who have received at least one treatment.
    approval is based on the latest data from the BOSTON III trial, which treated 402 patients with relapsed or incurable multiple myeloma with a 1-3 course of treatment.
    participants were randomly divided into once-a-week Xpovio combined with weekly boron tezomethami combined with low-dose dexamisong.
    progress-free lifetime (PFS) was evaluated at the main endpoint of the BOSTON III phase trial, and the overall mitigation rate (ORR), peripheral neuropathy rate, etc. were evaluated at the secondary endpoint.
    results showed that the median PFS was 13.9 months in patients receiving Xpovio combined treatment, compared with 9.5 months in the control group.
    orR (62.3%) in the Xpovio combined treatment group was significantly higher (76.4%) than the ORR (62.3%) that used boron-zomi jointly alone.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.